2-(4-Nitrophenyl)-4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-Nitrophenyl)-4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylic acid
• 英文别名: 2-(4-nitrophenyl)-4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylic acid
• 化学式: C24H23N3O5
• 分子量: 433.5
• InChiKey: SAXVOIRDGRQJST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  98.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• CHROMENIC PHYTOCANNABINOIDS, THEIR SYNTHESIS AND USE IN TREATMENT OR PREVENTION OF DISEASE
  申请人：Emerald Health Biotechnology España,S.L.U.

  公开号：EP3666765A1

  公开（公告）日：2020-06-17

  The present invention relates to a compound of the formula (I) or a solvate or co-crystal thereof wherein: - R is selected from the group consisting of: a C1-C6 alkyl, a C2-C8 alkenyl moiety, a C4-C12 dienyl or a C6-C18 trienyl moiety; - R1 is a C1-C6 alkyl moiety; - R2 is selected from the group consisting of: H and a C1-C6 alkyl moiety; - R3 is selected from the group consisting of: H and a C1-C6 alkyl moiety; - R4 is selected from the group consisting of: H, a C1-C6 alkyl moiety and a benzyl moiety. The present invention also relates to a process for producing said compound of the formula (I), or a solvate or co-crystal thereof, as well as a pharmaceutical composition comprising said compound of the formula (I), or a solvate or co-crystal thereof and at least one excipient. The present invention also relates to a compound of the formula (I), or a solvate or co-crystal thereof, for use in the treatment or prevention of a disease or condition.

  本发明涉及以下公式(I)的化合物或其溶剂或共晶体，其中：- R选自以下组：C1-C6烷基，C2-C8烯基基团，C4-C12二烯基或C6-C18三烯基；- R1是C1-C6烷基基团；- R2选自以下组：H和C1-C6烷基基团；- R3选自以下组：H和C1-C6烷基基团；- R4选自以下组：H，C1-C6烷基基团和苄基。本发明还涉及制备所述公式(I)的化合物或其溶剂或共晶体的方法，以及包括所述公式(I)的化合物或其溶剂或共晶体和至少一种赋形剂的药物组合物。本发明还涉及用于治疗或预防疾病或状况的公式(I)的化合物或其溶剂或共晶体。
• Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2719375A1

  公开（公告）日：2014-04-16

  The present invention relates to a pharmaceutical composition comprising one or more endocannabinoids, cannabinoids and/or modified versions thereof complexed with one or more lipoproteins, wherein said one or more endocannabinoids are selected from N-acylethanolamides, N-acyl dopamines, 2-acyl glycerols and 2-glyceryl ethers and wherein said one or more cannabinoids are selected from cannabinols, cannabidiols and tetrahydrocannabinols. Further, the invention relates to the use of said pharmaceutical composition in the treatment of a tumour in a mammal. Also, the invention relates to a method for modulating the activity of the hedgehog signaling pathway in a mammalian cell and the use of one or more endocannabinoids, cannabinoids and modified versions thereof in the differentiation of embryonic stem cells, progenitor cells and/or induced stem cells.

  本发明涉及一种药物组合物，该组合物包含与一种或多种脂蛋白复配的一种或多种内源性大麻素、大麻素和/或其改良剂，其中所述一种或多种内源性大麻素选自 N-酰乙醇酰胺、N-酰多巴胺、2-酰甘油和 2-甘油醚，所述一种或多种大麻素选自大麻酚、大麻二酚和四氢大麻酚。此外，本发明还涉及所述药物组合物在治疗哺乳动物肿瘤中的用途。此外，本发明还涉及一种调节哺乳动物细胞中刺猬信号通路活性的方法，以及在胚胎干细胞、祖细胞和/或诱导干细胞分化中使用一种或多种内大麻素、大麻素及其改良剂的方法。
• [EN] CHROMENIC PHYTOCANNABINOIDS, THEIR SYNTHESIS AND USE IN TREATMENT OR PREVENTION OF DISEASE<br/>[FR] PHYTOCANNABINOÏDES CHROMÉNIQUES, LEUR SYNTHÈSE ET LEUR UTILISATION DANS LE TRAITEMENT OU LA PRÉVENTION D'UNE MALADIE
  申请人：EMERALD HEALTH BIOTECHNOLOGY ESPANA S L U

  公开号：WO2020120582A1

  公开（公告）日：2020-06-18

  The present invention relates to a compound of the formula (I) or a solvate or co-crystal thereof (I) wherein: - R is selected from the group consisting of: a C1-C6 alkyl, a C2-C8 alkenyl moiety, a C4-C12 dienyl or a C6-C18 trienyl moiety; - R1 is a C1-C6 alkyl moiety; - R2 is selected from the group consisting of: H and a C1-C6 alkyl moiety; - R3 is selected from the group consisting of: H and a C1-C6 alkyl moiety; - R4 is selected from the group consisting of: H, a C1-C6 alkyl moiety and a benzyl moiety. The present invention also relates to a process for producing said compound of the formula (I), or a solvate or co-crystal thereof, as well as a pharmaceutical composition comprising said compound of the formula (I), or a solvate or co-crystal thereof and at least one excipient. The present invention also relates to a compound of the formula (I), or a solvate or co-crystal thereof, for use in the treatment or prevention of a disease or condition.